Providing innovation in personalized medicine for breast cancer chemotherapy management.
Rna Diagnostics is a cancer diagnostics company providing a platform of prognostic biomarker tools to help improve the lives of women undergoing chemotherapy for breast cancer. Founded in 2010, Rna Diagnostics’ first product is the RNA Disruption Assay™.
The RNA Disruption Assay™ (RDA™) provides physicians with an evaluation of how individual patients are responding to chemotherapy. If chemotherapy is working, the physician and patient can continue treatment with confidence. If chemotherapy is not working well enough, physicians may consider alternate therapies. For patients, this means avoiding harmful side effects and the possibility for improved survival outcomes.
Rna Diagnostics has clinical trials and collaborations in progress at multiple clinical research centres in Canada, Germany, Italy, Japan, Sweden, United Kingdom and the United States. The RNA Disruption Assay is available for clinical trial use from a state-of-the-art laboratory in Sudbury, Ontario, Canada.
Rna Diagnostics has the worldwide exclusive license from Laurentian University for this technology. It is anticipated that this technology will substantially improve the current treatment landscape for breast and other types of cancers.

Read what Professor Daniele Generali, RDA Clinical Research Collaborator has to say about Rna Diagnostics
Professor Daniele Generali
“RDA represents a major advance in the management of breast cancer therapy. It offers the promise of real time monitoring of patient response to chemo treatment. RDA will allow us to make better informed treatment decisions that will improve the lives of our patients.”Associate Professor in Medical Oncology
Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, Trieste, Italy
Meet the Rna Diagnostics Team
An experienced management team and a world renowned clinical advisory board providing a Real Time chemotherapy guidance tool
Rna Team
Board of Directors
Clinical Advisory Board
Rna Diagnostics’ Supporters
Supporters include:
Golden Triangle Angelnet
Health Technology Exchange
Rna Diagnostics receives support from organizations and individuals that believe RDA will provide critical information to physicians, improve the lives of women undergoing chemotherapy for breast cancer and will reduce healthcare costs.

Read what Nick Dipietro, Executive Director, Niagara Angel Network & Former President Of Patheon Inc. has to say about RDA
Nick Dipietro
“Rna Diagnostics’ RDA™ test will dramatically improve patient care and reduce health care costs. The underlying proprietary technology has the potential to create innovative products for the Canadian healthcare system and beyond. The experienced leadership team at Rna Diagnostics has the ability and drive to make this company a world success.”
Read what Dr. Maureen E. Trudeau has to say about RDA
Dr. Maureen E. Trudeau
“The RDA score could help us to predict which patients’ tumours will or will not respond to chemotherapy early in the course of treatment. This will allow a rapid change in treatment for those with unresponsive tumours.”Co-author and Chair of the Rna Diagnostics Clinical Advisory Board, Dr. Maureen E. Trudeau Professor of Medicine at the University of Toronto, Medical Oncologist at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, and co-chair of the breast cancer disease site group of Cancer Care Ontario.
For more information about investing in Rna Diagnostics, please contact:
John Connolly – Executive Vice-President Corporate Development
416-985-4361 • jconnolly@rnadiagnostics.com
An evolution in breast cancer chemotherapy management.